Literature DB >> 12824047

Novel IKK inhibitors: beta-carbolines.

Alfredo C Castro1, Luan C Dang, François Soucy, Louis Grenier, Hormoz Mazdiyasni, Maria Hottelet, Lana Parent, Christine Pien, Vito Palombella, Julian Adams.   

Abstract

Inhibitors of IkappaB kinase (IKK) have long been sought as specific regulators of NF-kappaB. A screening effort of the endogenous IKK complex allowed us to identify 5-bromo-6-methoxy-beta-carboline as a nonspecific IKK inhibitor. Optimization of this beta-carboline natural product derivative resulted in a novel class of selective IKK inhibitors with IC(50)s in the nanomolar range. In addition, we show that one of these beta-carboline analogues inhibits the phosphorylation of IkappaBalpha and subsequent activation of NF-kappaB in whole cells, as well as blocking TNF-alpha release in LPS-challenged mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824047     DOI: 10.1016/s0960-894x(03)00408-6

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  42 in total

Review 1.  NF-kappaB in carcinoma therapy and prevention.

Authors:  Matthew Brown; Jonah Cohen; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Expert Opin Ther Targets       Date:  2008-09       Impact factor: 6.902

Review 2.  Small-molecule inhibition of inflammatory β-cell death.

Authors:  M Lundh; S S Scully; T Mandrup-Poulsen; B K Wagner
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

3.  Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury.

Authors:  George W Farr; Christopher H Hall; Susan M Farr; Ramon Wade; Joshua M Detzel; Amielia G Adams; Jasen M Buch; Derek L Beahm; Christopher A Flask; Kui Xu; Joseph C LaManna; Paul R McGuirk; Walter F Boron; Marc F Pelletier
Journal:  Neuroscience       Date:  2019-02-07       Impact factor: 3.590

Review 4.  Inhibitory kappa B Kinases as targets for pharmacological regulation.

Authors:  Carly Gamble; Kathryn McIntosh; Rebecca Scott; Ka Ho Ho; Robin Plevin; Andrew Paul
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  A novel carboline derivative inhibits nitric oxide formation in macrophages independent of effects on tumor necrosis factor α and interleukin-1β expression.

Authors:  Ana Cristina G Grodzki; Bhaskar Poola; Nagarekha Pasupuleti; Michael H Nantz; Pamela J Lein; Fredric Gorin
Journal:  J Pharmacol Exp Ther       Date:  2014-12-23       Impact factor: 4.030

6.  A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.

Authors:  Karl Ziegelbauer; Florian Gantner; Nicholas W Lukacs; Aaron Berlin; Kinji Fuchikami; Toshiro Niki; Katsuya Sakai; Hisayo Inbe; Keisuke Takeshita; Mina Ishimori; Hiroshi Komura; Toshiki Murata; Timothy Lowinger; Kevin B Bacon
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

7.  IkappaB kinase is an essential component of the Tpl2 signaling pathway.

Authors:  Michael Waterfield; Wei Jin; William Reiley; Minying Zhang; Shao-Cong Sun
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

8.  Characterization of the inhibitor of kappaB kinase (IKK) complex in granulosa cell tumors of the ovary and granulosa cell tumor-derived cell lines.

Authors:  Stacey Jamieson; Peter J Fuller
Journal:  Horm Cancer       Date:  2013-05-15       Impact factor: 3.869

Review 9.  Advances in targeting IKK and IKK-related kinases for cancer therapy.

Authors:  Dung-Fang Lee; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

Review 10.  Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.

Authors:  Sander W Tas; Margriet J B M Vervoordeldonk; Paul P Tak
Journal:  Curr Gene Ther       Date:  2009-06       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.